Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: Crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 Å resolution
暂无分享,去创建一个
Punit Kaur | Sujata Sharma | A. S. Ethayathulla | T. Singh | P. Kaur | T. Jabeen | R. Singh | Sujata Sharma | Tej P Singh | Talat Jabeen | Rajendra Kumar Singh | A S Ethayathulla
[1] R. Sperling. Eicosanoids in rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.
[2] C. Betzel,et al. Structural basis of phospholipase A2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 A crystal structure. , 2002, Biochemistry.
[3] M. Gelb,et al. Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue , 1990, Science.
[4] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[5] D. Dewitt. Prostaglandin endoperoxide synthase: regulation of enzyme expression. , 1991, Biochimica et biophysica acta.
[6] Sujata Sharma,et al. Design of specific peptide inhibitors for group I phospholipase A2: structure of a complex formed between phospholipase A2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 A resolution reveals unique features. , 2003, Biochemistry.
[7] J.-P. Wery,et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.
[8] G. N. Ramachandran,et al. Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.
[9] A. Szabó,et al. Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). , 1995, Current opinion in structural biology.
[10] M. Feldman,et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.
[11] I. Pavord,et al. Induced sputum eicosanoid concentrations in asthma. , 1999, American journal of respiratory and critical care medicine.
[12] E. Granström. Prostaglandin biochemistry, pharmacy and physiological function. The prostaglandins, thromboxanes and leukotrienes. , 1983, Acta obstetricia et gynecologica Scandinavica. Supplement.
[13] D. Velmurugan,et al. Crystal structures of the free and anisic acid bound triple mutant of phospholipase A2. , 2003, Journal of molecular biology.
[14] J. J. Rosa,et al. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. , 1993, Science.
[15] J. Navaza,et al. AMoRe: an automated package for molecular replacement , 1994 .
[16] M. Perbandt,et al. Crystal Structure of a Complex Formed between a Snake Venom Phospholipase A2 and a Potent Peptide Inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å Resolution* , 2002, The Journal of Biological Chemistry.
[17] L. Nieba,et al. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. , 1996, Analytical biochemistry.
[18] P. Majerus,et al. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.
[19] Daniel Picot,et al. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.
[20] P. Sigler,et al. Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. , 1990, Science.
[21] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[22] S S Abdel-Meguid,et al. High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX). , 1996, Journal of medicinal chemistry.
[23] M. Sundaralingam,et al. Crystal structure of the complex of bovine pancreatic phospholipase A2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol,. , 1997, Biochemistry.
[24] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[25] C. Betzel,et al. Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). , 2002, Acta crystallographica. Section D, Biological crystallography.
[26] K. Sharp,et al. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.
[27] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[28] C. Betzel,et al. First structural evidence of a specific inhibition of phospholipase A2 by alpha-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. , 2002, Journal of molecular biology.
[29] P. Elsbach,et al. Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.